Nuvalent (NUVL) Stock Overview

A clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. More details

NUVL fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 82.8% below our estimate of its fair value

Revenue is forecast to grow 56.88% per year

Analysts in good agreement that stock price will rise by 35.2%

Risk Analysis

Makes less than USD$1m in revenue ($0)

Currently unprofitable and not forecast to become profitable over the next 3 years

NUVL Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Pharmaceuticals & Biotech opportunity

Unicycive Therapeutics

Fair Value from

stuart_roberts

US$21.5363.1% undervalued

Looking to be second time lucky with a game-changing new product

Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.

Read narrative

Nuvalent, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Nuvalent
Historical stock prices
Current Share Price	US$105.28
52 Week High	US$113.02
52 Week Low	US$68.64
Beta	1.15
1 Month Change	2.47%
3 Month Change	3.13%
1 Year Change	42.99%
3 Year Change	158.42%
5 Year Change	n/a
Change since IPO	461.49%

Recent updates

Seeking Alpha • Nov 05

Nuvalent: Interesting Product, But Aggressive Valuation

Summary NUVL is approaching the precipice of a first targeted therapy approval in lung cancer. They also have an increasingly deep pipeline of therapies, with an audacious phase 3 trial spinning up in ALK-positive NSCLC. Cash position remains strong as well, but the market is pricing in too much success for me to be comfortable at this time. Read the full article on Seeking Alpha

Analysis Article • Jun 16

We're Hopeful That Nuvalent (NASDAQ:NUVL) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Seeking Alpha • Jan 22

Nuvalent: A First Look

Summary Nuvalent, Inc. shares have fallen approximately 30% after promising updates on its two lead NSCLC candidates rallied the stock to all-time highs. Nuvalent focuses on next-gen TKIs for NSCLC, with lead candidates zidesamtinib and NVL-665 showing promising clinical trial results and key FDA designations. With pivotal data expected in 2025 and a strong cash position, Nuvalent merited further investigation. A first look at this clinical stage biotech concern follows in the paragraphs below. Read the full article on Seeking Alpha

Seeking Alpha • Jan 10

Nuvalent: A Logical Acquisition Target

Summary Nuvalent's NVL-655 and Zidesamtinib show strong potential as first-line therapies for NSCLC, with impressive Phase I/II trial results and FDA designations. Nuvalent's robust financial position and pipeline make it a prime M&A target, with potential suitors like Pfizer, AstraZeneca, and Novartis. Downside risks include regulatory setbacks, commercialization challenges, strong competition, and financial management, but Nuvalent's cash runway is healthy until 2028. I plan to establish a NUVL position soon, anticipating significant catalysts in 2025 and beyond, with a strategy to capitalize on M&A speculation. Read the full article on Seeking Alpha

Seeking Alpha • Dec 07

Nuvalent: Steps Toward That Favorable Entry Point

Summary Nuvalent, Inc. has promising drugs, zidesamtinib and NVL-655, targeting NSCLC with encouraging data, particularly in addressing brain metastases and resistance. Despite strong clinical prospects, the current valuation above $6 billion is too high, given no commercial launches or approvals yet. Financially, NUVL has a cash runway of 13-14 quarters, but accelerating drug development costs could shorten this period. I remain cautious, giving it a "sell" due to potential share price declines before approvals, despite optimism for clinical outcomes. Read the full article on Seeking Alpha

Seeking Alpha • Sep 23

Nuvalent: Promising Data Keeps Validating Pipeline And Platform

Summary Nuvalent's lead candidates, NVL-520 and NVL-655, show promising efficacy and safety in Phase 1/2 trials. Both drugs have received FDA Breakthrough Therapy and orphan drug designations, with pivotal Phase 2 data expected in 2025 and potential approvals by 2026. The company completed a $500 million secondary offering, reflecting strong investor interest and providing the cash runway through Phase 3. Nuvalent's stock is poised for a gradual uptrend and relative outperformance, supported by its robust data and potential multi billion-dollar revenue opportunities for its wholly owned lead candidates. Read the full article on Seeking Alpha

Seeking Alpha • Sep 17

Nuvalent: Likely Approvals Coming Up Do Not Justify This Valuation

Summary Nuvalent shows promise with strong clinical data for zidesamtinib and NVL-655 in treating ROS1- and ALK-positive NSCLC, addressing acquired resistance issues. The company boasts significant cash reserves, potentially sufficient to reach commercial stage without further fundraising, enhancing its financial stability. Despite promising science, Nuvalent targets niche markets with limited patient subsets, impacting potential sales and market penetration. At a $7.3 billion valuation, Nuvalent's near-term growth seems unlikely; I would look for a much better entry point. Read the full article on Seeking Alpha

Seeking Alpha • Jun 24

Nuvalent: Making Precise Progress In Its Oncology Pipeline

Summary Nuvalent, Inc. is a biotechnology company with precision-targeted treatments using kinase inhibitors for non-small cell lung cancer. NVL-520 targets ROS1-positive cancer and addresses treatment resistance, kinase mutations, and CNS-related adverse events, which limit existing treatments for NSCLC. NVL-655 is an ALK-selective inhibitor to overcome treatment resistance and CNS-related adverse events in ALK-driven NSCLC. Phase 1/2 updated data to be released in the second half of 2024 and Phase 2 data on its two novel candidates in 2025. Nuvalent's promising pipeline, innovative approach, and market needs present an attractive speculative opportunity with the potential for a significant valuation boost over the next 6 to 12 months. Read the full article on Seeking Alpha

Seeking Alpha • Jun 14

Nuvalent: NVL-655 Could Bring Blockbuster Potential

Summary Nuvalent's NVL-655 received FDA Breakthrough Therapy Designation for ALK+ NSCLC, showing potential as a vital therapy. Nuvalent's pipeline includes innovative kinase therapies for NSCLC, with NVL-655 and Zidesamtinib showing promise in clinical trials. NVL-655 has the potential to become a blockbuster drug, with peak sales estimates supporting a higher share price for Nuvalent in the future. Read the full article on Seeking Alpha

Seeking Alpha • Feb 26

Nuvalent: Pivotal NSCLC Programs Progressing With Additional Data In 2024

Summary Nuvalent, Inc. expects final results from the phase 1 ARROS-1 study, using NVL-520 for the treatment of patients with ROS-1 positive non-small cell lung cancer, in 2024 at a medical meeting. Final results from the phase 1 ALKOVE-1, using NVL-655 for the treatment of patients with ALK-positive non-small cell lung cancer, expected in 2024 at a medical meeting. The global non-small cell lung cancer market size is projected to reach $36.9 billion by 2031; About 1% to 3% have ROS-1 mutation and 3% to 5% have ALK mutation. NVL-330 is another candidate which could help company expand its presence in the NSCLC market even further, targeting patients with HER2 expression. Read the full article on Seeking Alpha

Shareholder Returns

	NUVL	US Biotechs	US Market
7D	2.6%	1.3%	2.2%
1Y	43.0%	42.0%	31.1%

Return vs Industry: NUVL matched the US Biotechs industry which returned 42% over the past year.

Return vs Market: NUVL exceeded the US Market which returned 31.1% over the past year.

Price Volatility

Is NUVL's price volatile compared to industry and market?
NUVL volatility
NUVL Average Weekly Movement	4.4%
Biotechs Industry Average Movement	10.7%
Market Average Movement	7.3%
10% most volatile stocks in US Market	16.1%
10% least volatile stocks in US Market	3.2%

Stable Share Price: NUVL has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: NUVL's weekly volatility (4%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2017	234	Jim Porter	nuvalent.com

Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; Neladalkib (NVL-655), a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR that is in Phase 1a/1b clinical trial. Nuvalent, Inc. has a strategic partnership with Guardant Health, Inc. to develop companion diagnostics therapies.

Nuvalent, Inc. Fundamentals Summary

How do Nuvalent's earnings and revenue compare to its market cap?
NUVL fundamental statistics
Market cap	US$8.32b
Earnings (TTM)	-US$450.07m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-18.5x

P/E Ratio

Is NUVL overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NUVL income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$450.07m
Earnings	-US$450.07m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	-5.70
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did NUVL perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/05/11 09:28
End of Day Share Price	2026/05/08 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Nuvalent, Inc. is covered by 25 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Colleen Kusy	Baird
Etzer Darout	Barclays
John Newman	Canaccord Genuity

Nuvalent (NUVL) Stock Overview

Rewards

Risk Analysis

Looking to be second time lucky with a game-changing new product

Nuvalent, Inc. Competitors

Vaxcyte

Krystal Biotech

Halozyme Therapeutics

Praxis Precision Medicines

Price History & Performance

Recent News & Updates

Nuvalent Advances Toward FDA Decision With NDA Submission for Neladalkib in ALK-Positive NSCLC

Chief Legal Officer & Secretary notifies of intention to sell stock

Nuvalent, Inc., Annual General Meeting, Jun 16, 2026

Nuvalent Inc Presents New Clinical and Preclinical Data for Zidesamtinib

Nuvalent, Inc. Announces Submission of New Drug Application to Fda for Neladalkib in Tki Pre-Treated Advanced Alk-Positive Nsclc

CFO & Treasurer exercised options and sold US$1.2m worth of stock

Recent updates

Nuvalent Advances Toward FDA Decision With NDA Submission for Neladalkib in ALK-Positive NSCLC

Chief Legal Officer & Secretary notifies of intention to sell stock

Nuvalent, Inc., Annual General Meeting, Jun 16, 2026

Nuvalent Inc Presents New Clinical and Preclinical Data for Zidesamtinib

Nuvalent, Inc. Announces Submission of New Drug Application to Fda for Neladalkib in Tki Pre-Treated Advanced Alk-Positive Nsclc

CFO & Treasurer exercised options and sold US$1.2m worth of stock

Consensus revenue estimates decrease by 46%, EPS upgraded

Chief Legal Officer & Secretary notifies of intention to sell stock

CEO, President & Director recently sold US$2.7m worth of stock

Chief Development Officer notifies of intention to sell stock

Nuvalent, Inc. Announces Board Changes

Nuvalent, Inc. Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced Ros1-Positive NSCLC

Nuvalent, Inc. has completed a Follow-on Equity Offering in the amount of $500.000096 million.

Chief Legal Officer & Secretary notifies of intention to sell stock

Nuvalent, Inc. has filed a Follow-on Equity Offering in the amount of $500 million.

Price target increased by 9.9% to US$130

Nuvalent, Inc. Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK- Positive NSCLC

Nuvalent: Interesting Product, But Aggressive Valuation

Chief Legal Officer & Secretary notifies of intention to sell stock

Nuvalent, Inc. Presents Preliminary Data for Neladalkib in Advanced ALK-Positive Solid Tumors Beyond NSCLC at ESMO Congress 2025

Chief Legal Officer & Secretary notifies of intention to sell stock

CFO & Treasurer exercised options and sold US$2.2m worth of stock

Nuvalent, Inc. Announces the Completion of Its New Drug Application Submission to the U.S. Food and Drug Administration for Zidesamtib in Tyrosine Kinase Inhibitor Pre-Treated Patients with Advanced Rios1-Positive Non-Small Cell Lung Cancer

CEO, President & Director exercised options and sold US$1.6m worth of stock

Nuvalent, Inc. Presents Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-Treated Patients with Advanced ROS1-Positive NSCLC at WCLC 2025

CEO, President & Director exercised options and sold US$1.5m worth of stock

Nuvalent, Inc. to Present Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-Treated Patients with Advanced ROS1-Positive NSCLC at WCLC 2025 Presidential Symposium

Nuvalent, Inc. Announces Initiation of ALKAZAR Phase 3 Randomized, Controlled Trial Evaluating Neladalkib for Patients with TKI-naive ALK-Posive NSCLC

CEO, President & Director exercised options and sold US$1.7m worth of stock

Chief Scientific Officer exercised options and sold US$552k worth of stock

New major risk - Revenue and earnings growth

Nuvalent, Inc. Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-Treated Patients with Advanced Ros1-Positive NSCLC

CEO, President & Director exercised options and sold US$1.3m worth of stock

Nuvalent, Inc. Appoints Christy Oliger to Board of Directors

We're Hopeful That Nuvalent (NASDAQ:NUVL) Will Use Its Cash Wisely

Nuvalent, Inc. Announces Resignation of Emily Conley from the Board and from All Committees of the Board

CEO, President & Director exercised options and sold US$1.1m worth of stock

Nuvalent, Inc. Announces Leadership Promotions

Nuvalent, Inc. Announces Publication in Molecular Cancer Therapeutics Reinforcing Rational Molecular Design of Zidesamtinib as a Novel ROS1-Selective Inhibitor

CEO, President & Director exercised options and sold US$1.1m worth of stock

Nuvalent, Inc. Announces Board Changes

CEO, President & Director exercised options and sold US$1.3m worth of stock

Chief Development Officer exercised options and sold US$2.4m worth of stock

CEO, President & Director exercised options and sold US$1.4m worth of stock

Nuvalent: A First Look

CEO, President & Director exercised options and sold US$1.3m worth of stock

Nuvalent: A Logical Acquisition Target

CEO, President & Director exercised options and sold US$1.6m worth of stock

Nuvalent, Inc. Plans to Initiate the Phase 3 Global, Randomized, Controlled ALKAZAR Trial in First Half of 2025

Nuvalent: Steps Toward That Favorable Entry Point

CFO & Treasurer exercised options and sold US$679k worth of stock

CEO, President & Director exercised options and sold US$1.6m worth of stock

Nuvalent Appoints Alice T. Shaw to its Scientific Advisory Board

CFO & Treasurer exercised options and sold US$613k worth of stock

CEO, President & Director notifies of intention to sell stock

CFO & Treasurer notifies of intention to sell stock

Nuvalent: Promising Data Keeps Validating Pipeline And Platform

Nuvalent, Inc. has completed a Follow-on Equity Offering in the amount of $500 million.

Nuvalent: Likely Approvals Coming Up Do Not Justify This Valuation

Nuvalent, Inc. Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines

Price target increased by 8.1% to US$111

Nuvalent, Inc. has filed a Follow-on Equity Offering in the amount of $350 million.